<DOC>
	<DOCNO>NCT00593593</DOCNO>
	<brief_summary>This study 4 phase : screening phase ( visit 1 ) , treatment phase ( visit 2 - 6 mths treatment initiation ) , end treatment phase ( visit 3 - end year 1 ) . Only case serious adverse event ( SAE ) arise , follow phase ( visit 4 ) .</brief_summary>
	<brief_title>Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Subject fulfil criterion subscription AVODART mention SPC Subject diagnose benign prostate hyperplasia Subject 's prostate volume equal great 30 cm3 Known hypersensitivity AVODART compound Suffers serious illness either properly control per investigator´s judgment could interfere subject´s compliance trial Receives treatment enzyme inhibitor CYP3A4 CYP3A5 . History severe liver failure</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>benign prostate hyperplasia</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>pharmacovigilance</keyword>
</DOC>